Patent ID: 7846432

Claim:
A method for inducing lysis of a tumor cell that expresses EGFR, comprising: contacting said tumor cell with an antigen binding molecule in an amount effective to induce lysis of said tumor cell, wherein said antigen binding molecule comprises a heavy chain variable domain and a light chain variable domain, wherein said heavy chain variable domain comprises: (a) a CDR1 selected from the group consisting of: SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:123, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:125; and (b) the CDR2 of SEQ ID NO:79; and (c) the CDR3 of SEQ ID NO:107; and wherein said light chain variable domain comprises: (a) the CDR1 of SEQ ID NO:111 or SEQ ID NO:113; and (b) the CDR2 of SEQ ID NO:115; and (c) the CDR3 of SEQ ID NO:117, wherein said antigen binding molecule binds to EGFR expressed on said tumor cell and is capable of competing with the ICR62 antibody for binding to EGFR, and wherein said antigen binding molecule comprises a glycoengineered Fc region and has at least one increased effector function.